Three-Year Longitudinal Immune Trajectory: The Triple Axis Sustaining mRNA Vaccine Protection in Immunocompromised Patients
##1. Uncertainty and Challenges Regarding Long-Term Protection in Immunocompromised Populations From the early stages of the COVID‑19 pandemic, immunocompromised patients have been managed as a high‑risk group due to concerns that post‑vaccination antibody responses would be weak or short‑lived. In particular, the waning of immunity over time was expected to be more pronounced than in the general population, yet high‑resolution data tracking immunity beyond three years and demonstrating protection against multiple variants have been lacking.
##2. COVAXID Three‑Year Prospective Study: Immune Analysis Across 21 Variants The investigators conducted the prospective COVAXID study over 36 months, closely monitoring a cohort of immunocompromised participants. Beyond measuring binding antibody titres, they assessed pseudo‑neutralisation activity against 21 variants, including the latest Omicron sub‑lineages, to evaluate functional protection. Contrary to early concerns, participants who had received booster doses and accumulated infection exposure showed antibody levels and neutralising capacity that remained stable or even increased up to the three‑year mark.
##3. Synergy of Hybrid and Passive Immunity: A Novel Role for IGRT A central finding of this study is that hybrid immunity—derived from vaccination combined with natural infection—creates a broader and more robust defense against variant viruses. Notably, immunoglobulin replacement therapy (IGRT) contributed passive immunity that complemented vaccine‑induced active immunity, elevating overall antibody levels. Throughout this process, CD4⁺ T‑cell responses remained robust, supporting the stability of cellular immunity.
##4. Why It Matters: Personalized Immune Profiling for Tailored Protection Strategies The significance of this work lies in providing evidence to shift protection strategies for immunocompromised patients from a uniform booster approach to individualized management based on each patient’s immune history. By integrating infection history, IGRT use, and booster count, clinicians can construct personalized immune roadmaps that avoid unnecessary over‑vaccination while delivering precise passive immunity during periods of heightened risk. This represents a scientifically rigorous and actionable roadmap for restoring normalcy in vulnerable populations.
BACKGROUND: Immunocompromised individuals were identified early in the pandemic as being at increased risk of severe COVID-19 and have demonstrated variable immune responses to SARS-CoV-2 vaccination. Although coordinated vaccination programmes are now well established, their long-term effects on sustained immunity in the present patient populations remain insufficiently understood. METHODS: The prospective SARS-CoV-2 mRNA vaccine trial COVAXID was conducted in a well‑characterised, real‑world cohort of 539 immunocompromised and healthy individuals across 21 subgroups, organised into six main categories. At the 36-month time point, 218 participants remained. Participants provided blood samples for assessment of binding antibody titres and pseudo‑neutralisation activity against ancestral SARS‑CoV‑2 and 21 variants, including Omicron sub‑lineages. T cell responses were evaluated in a defined subset of participants. Immunogenicity outcomes were analysed over a three-year period in relation to SARS‑CoV‑2 vaccination, SARS‑CoV‑2 infection, and immunoglobulin replacement therapy (IGRT). FINDINGS: Between years two and three, antibody titres and neutralisation capacity showed a consistent pattern of maintenance or increase across most study groups and subgroups. These increases were driven by cumulative exposure to vaccine booster doses, SARS‑CoV‑2 infection, and, in some cases, passive immunisation through IGRT. CD4 INTERPRETATION: The findings support continued, tailored vaccination strategies for elderly and immunocompromised individuals. Integrating immune monitoring with infection history and adjunctive therapies may help refine booster policies, optimise protection, and strengthen future vaccination programmes for high‑risk populations. FUNDING: The present studies were supported by the European Research Council, Karolinska Institutet, Knut and Alice Wallenberg Foundation, Nordstjernan AB, Region Stockholm, and the Swedish Research Council.
These data demonstrate, over a three‑year follow‑up, how the complementary mechanisms of active and passive immunity operate long‑term in immunocompromised populations. Beyond confirming vaccine efficacy, the quantification of the impact of externally supplied immune resources such as IGRT on patients’ immune trajectories provides a solid foundation for a precision‑public‑health model tailored to vulnerable groups in response to future emerging variants, representing significant scholarly value.